NCT04076579View on ClinicalTrials.gov

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 17, 2020

Primary Completion Date

January 30, 2023

Study Completion Date

September 26, 2024

Conditions
SarcomaSarcoma Metastatic
Interventions
DRUG

Olaparib

Olaparib taken by mouth twice daily

DRUG

Trabectedin

Trabectedin administered intravenously (IV) every 21 days

Trial Locations (1)

48109

University of Michigan Rogel Cancer Center, Ann Arbor

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER